Toku Eyes founder Dr Ehsan Vaghefi says his company's AI software can analyse eye images faster than a human clinician and pick up things they might miss. Auckland-based Toku Eyes seems…
Toku EyesApril 19, 2023
Happy to announce the winner of the 42PLUS1 US Satellite Award! Congratulations Toku Eyes! 🚀🚀🚀 What a great innovation you shared at the DxPx Conference stage about the artificial intelligence…
Toku EyesAugust 1, 2022
The company uses AI to detect eye health, as well as diabetes and cardiovascular conditions There are 43 million people in the world who are blind, and another 295 million who have…
Toku EyesJune 1, 2022
Toku Eyes, a New Zealand-based healthcare AI company, is launching its tool that assesses heart risk through a retinal scan in the U.S. The tool, called CLAiR, uses an AI…
Toku EyesJune 1, 2022
An Artificial Intelligence retinal screening tool, developed in New Zealand, is being used in 20 eye clinics in India and is about to launch in the United States. THEIA has…
Toku EyesMay 26, 2022
Around 280,000 New Zealanders have diabetes, with the disease almost three times more common in Māori than non-Māori. And mortality rates for the disease are nine times higher for Māori…
Toku EyesMay 10, 2022
Detecting diabetes is about to get a whole lot easier. A Kiwi company has created a revolutionary technology called THEIA, which uses AI to examine blood vessels in the eye…
Toku EyesMay 3, 2022
The trial of an Artificial Intelligence retinal screening tool, developed in New Zealand, showed it did not miss any referable disease for diabetic patients at risk of eye disorders. THEIA…
Toku EyesJuly 25, 2021
Ehsan Vaghefi has been a guide all his life. After all, when other children his age were being helped across the street by their parents, he was helping his blind…
Toku EyesJuly 19, 2021
New Zealand startup Toku Eyes, which has built an artificial intelligence platform to improve early detection of eye diseases such as macular degeneration, glaucoma and other diseases observable via the…
Toku EyesJune 29, 2021
Toku Eyes has completed its first prospective clinical trial of its artificial intelligence (AI) screening platform Theia, designed to support more cost-effective diagnosis and prognosis of eye disorders. The trial,…
Toku EyesJune 29, 2021
Auckland startup Toku Eyes has raised $3.6 million to develop its AI software - which founder Associate Professor Ehsan Vaghefi says can analyse eye images faster than a human clinician…
Toku EyesJune 28, 2021
A multi-center prospective evaluation of THEIA to detect diabetic retinopathy (DR) and diabetic macular edema (DME) in the New Zealand screening program Purpose: to assess the efficacy of THEIA, an…
Toku EyesJune 23, 2021
